Case Type: Mergers & Acquisitions

RMG Acquisition Corp. (RMG) relating to its merger agreement with Romeo Power. Under the terms of the agreement, RMG shareholders will retain ownership of 17% of the combined company.

American Renal Associates Holdings, Inc. (ARA) relating to its acquisition by Nautic Partners, LLC. Under the terms of the agreement, ARA shareholders shall be entitled to receive $11.50 in cash for each share of ARA common stock owned.

Seacoast Commerce Banc Holdings (SCBH) related to the merger agreement with Enterprise Financial Services Corp. Under the terms of the merger agreement, the company will be acquired by Enterprise, and Seacoast stockholders will receive 0.5061 shares of Enterprise common stock for each share of Seacoast common stock owned.

Hennessy Capital Acquisition Corp. IV. (HCAC) related to the merger agreement with Canoo Holdings, Ltd. Under the terms of the merger agreement, the company will acquire Canoo through a reverse merger that will result in Canoo becoming a publicly-listed company.

Virtusa Corporation (VRTU) related to its sale to Baring Private Equity Asia. Under the terms of the agreement, Virtusa shareholders will receive $51.35 per share for each share of Virtusa stock owned.

Trine Acquisition Corp, Inc. (TRNE) related to the busienss combination with Desktop Metal for its 3D printing business.

Aimmune Therapeutics, Inc. (AIMT) related to its sale to Sociétés des Produits Nestlé, S.A. Under the terms of the agreement, Aimmune shareholders will receive $34.50 per share for each share of Aimmune stock owned.

Immunomedics, Inc. (IMMU) related to its sale to Gilead Sciences, Inc. Under the terms of the agreement, Immunomedics shareholders will receive $88.00 per share for each share of Immunomedics stock owned.

BMC Stock Holdings, Inc. (BMCH) related to its sale to Builders First Source, Inc. Under the terms of the agreement, BMC shareholders will receive 1.3125 shares of Builder First Source stock for each share of BMC stock owned.

Akcea Therapeutics, Inc. (AKCA) related to its sale to Ionis Pharmaceuticals, Inc. Under the terms of the agreement, Akcea shareholders will receive $18.15 in cash for each share of Akcea common stock owned.